China will be Asia’s largest stem cell base

Author:ANROSOFT_market survey report Company,market survey report services.( http://anrosoft.com )

“At present, Chinese medicine and our city have formed a framework agreement for financing at the same time we are.” Yesterday, the North Branch of Shenzhen Biology Technology Co., Ltd. (hereinafter referred to as “North Branch biology”) Chairman Dr. Hu Xiang told “First Financial Daily” .

The so-called framework agreement, that is, the North Branch will be located in biology Taizhou City, China Medical Board of the common set up Asia’s largest industrial base of the stem cells, including the establishment of the North Branch Stem Cell Institute, Jiangsu Province Engineering Research Center for Stem Cell, stem cell bank in Jiangsu Province and Jiangsu Provincial Research Center of Clinical Biology.

Business model innovation

“Base stem cell industry will be an area of 30,000 square meters, while Chinese medicine is also an urban capacity of one million people were stem cell bank, compared to 100,000 common stem cell bank, we are now the biggest in Asia. Of course , we have the storage capacity should also be continuously used for clinical, and not just a store. “said David Hu.

I understand that the stem cell bank required upfront investment 30 million yuan, mainly funded by the North Branch biology. It is reported that stem cell bank stem cells apart from the preservation of resources, the technology will also continue to study and eventually to clinical application.

David Hu and so full of confidence of the industry is another reason for him to explore multi-year operation of the business model. In addition to the technical R & D, the North Branch and biology through co-operation set up medical institutions throughout the therapeutic relationship, to build a network of stem cell applications, and then on to the output of technical cooperation agencies, in order to provide patients with personalized treatment, again in accordance with the ratio and the hospital must share treatment.

As far as cooperation with the North Branch of the medical institutions have revealed that patients receiving the current “neural stem cell transplantation” required to pay a high treatment costs. Foreign patients a course of treatment fees are around 20,000 U.S. dollars, the domestic treatment of patients around a 5 million yuan. David Hu also revealed that the back section current form is pretty good.

David Hu said that if the traditional model of stem cell technology to develop in accordance with the drugs, after the upper reaches of research, pilot studies, clinical Wait for approval, three clinical studies of new drugs to obtain certification, the final aspect, the average investment cycle may be more than 10 years, investment limit of not less than one hundred million U.S. dollars, too risky.

The prospect of stem cell therapy industry

Research has shown that by 2015, the global stem cell medical services around the potential market size for the 80 billion U.S. dollars. So far, this area has also attracted a lot of people the world’s top venture capital for sustained attention.

But the industry is the coexistence of opportunities and risks. Concord, according to the Tianjin Stem Cell Genetic Engineering Professor Qiu Ltd., the hematopoietic stem cell technology has been widely used in clinical for several decades, but the non-hematopoietic stem cell technology is still only in animal experiments and early clinical trial stage, the technology is not sophisticated.

At present, cord blood stem cells can be used to treat a variety of blood diseases and immune system diseases, including hematological malignancies, hemoglobin disease, bone marrow failure, such as malignant diseases.

According to David Hu introduction, by the research ethics and other restrictions on some of the reasons, at present Europe and the United States and other countries in the technical aspects of stem cell research is not very ideal, but rather the Chinese in this regard early start, the earlier the formation of the advantages of industrialization.

David Hu disclosed that there are already several on the North Branch has completed its due diligence biology, he said that financing will be used for stem cell funding base to promote the follow-up project.

Related analysis market survey Report >>

• The next 20 years the field of materials technology 15 key technologies
• Hydrophilic foam material up-to-date technology available
• Chinese investigate the distribution of non-metallic mineral analysis of the main research
• Competitive structure of polysilicon industry market survey research
• Investors involved in the production of polysilicon to avoid blind
• Gold nanoparticles analysis of market research
• New materials, glass fiber as a sunrise industry
• Lithium iron phosphate patent analysis market research
• Building up a new industrial revolution Materials
• European-style windows and doors market situation and development trend of the Investigation and Analysis
• Graphite will replace silicon with nano-semiconductor materials
• Biodegradable plastics industry market research analysis
• Application of biodegradable plastics global warming
• Biodegradable Plastics Market survey research Analysis
• Chinese light-emitting diode LED Industry Analysis

Contact us,I’m
Online!